Clinical Data ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D Pharmaceutical TechnologyData presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes.Clinical DataCardiovascularRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Data presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes. Clinical DataCardiovascularRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave CrashesNext: Viridian reports positive results from elegrobart phase 3 trial Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
